Rating Rationale
September 06, 2022 | Mumbai
Bajaj Healthcare Limited
Rated amount enhanced
 
Rating Action
Total Bank Loan Facilities RatedRs.383 Crore (Enhanced from Rs.292 Crore)
Long Term RatingCRISIL BBB/Positive (Reaffirmed)
Short Term RatingCRISIL A3+ (Reaffirmed)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its ‘CRISIL BBB/Positive/CRISIL A3+ ratings on the bank facilities of Bajaj Healthcare Limited (BHL).

 

The ratings continue to reflect established market position of BHL, backed by a strong and diversified clientele and healthy financial risk profile. These strengths are partially offset by exposure to intense competition in the bulk drugs industry and large working capital requirement.

 

Revenue grew by around 3% on-year in fiscal 2022; however, the operating margin declined to 17.56% in fiscal 2022 from 21.59% in fiscal 2021 owing to increase in raw material costs and the limited ability of the company to pass on the price hike. Scale of operations should continue to be stable while the operating margin is likely to moderate yet remain better than pre-pandemic levels. Inventory has been high in fiscal 2023 due to an anticipated delay in shipment owing to freight-related issues in China and also as a buffer in case of any supply disruption, leading to higher bank limit utilization. Inventory may reduce in the coming years, with the market expected to stabilize, and thereby strengthen the credit risk profile of the company; this will remain a key monitorable.

Key Rating Drivers & Detailed Description

Strengths:

 

  • Healthy financial risk profile: Financial risk profile should remain supported by steady accretion to reserve. Net worth was Rs 328.0 crore as on March 31, 2022, and total outside liabilities to adjusted net worth ratio was 1.2 times. Debt protection metrics were robust, with interest coverage and net cash accrual to adjusted debt ratios of 9.50 times and 0.34 time, respectively, in fiscal 2022.

 

Weaknesses:

  • Exposure to intense competition in the bulk drugs industry: The bulk drugs industry comprises numerous players, and the consequent intense competition may continue to constrain scalability, pricing power and profitability. 

 

  • Large working capital requirement: Gross current assets (GCAs) were high at around 214 days as on March 31, 2022, driven by inventory and debtors of 104 days and 99 days, respectively. Debtors have historically been 80-90 days and may remain so over the medium term as well. Inventory level increased from 69 days on March 31, 2021, mainly to tackle delay in shipments and any probable supply disruption; it is likely to reduce in fiscal 2023 and will remain closely monitored. 

Liquidity: Adequate

Cash accrual is projected at Rs 77-95 crore per annum, sufficient to meet the yearly debt obligation of just Rs 10-12 crore over the medium term; the surplus cash will aid financial flexibility. Bank limit utilization was 90% during the 12 months through May 2022. Current ratio was 1.23 times as on March 31, 2022, and cash and bank balance stood at Rs 3.04 crore.

Outlook: Positive

The business and financial risk profiles of BHL should improve over the medium term, backed by extensive experience of the promoters, favourable demand for key products and new capacities acquired.

Rating Sensitivity factors

Upward factors

  • Improvement in the working capital cycle owing to better inventory management, resulting in GCAs below 200 days
  • Decline in debt levels leading to healthy financial flexibility, strengthening the overall credit risk profile 

 

Downward factors

  • Decline in revenue or operating margin, leading to cash accrual below Rs 35 crore
  • Further stretch in the working capital cycle leading to GCA days of more than 220 days or any large, debt-funded capital expenditure

About the Company

BHL was incorporated in 1993 as a private-limited company by Mr Sajankumar R Bajaj and his family members; it got reconstituted into a closely held public-limited company in 2005. The company was listed in the small and medium enterprise segment of the Bombay Stock Exchange in May 2016 and later migrated to the Main Board of BSE in May 2019. It manufactures active pharmaceutical ingredients and formulations in the form of tablets, capsules, and powder; it also exports bulk drugs to Europe, USA, Australia, and Africa.

Key Financial Indicators

As on / for the period ended March 31

 

Q1 Fiscal 2023

2022*

2021

Operating income

Rs crore

172.07

679.89

658.32

Reported profit after tax (PAT)

Rs crore

12.02

71.39

83.11

PAT margin

%

6.98

10.48

12.62

Adjusted debt/adjusted networth

Times

0.78

0.78

0.70

Interest coverage

Times

6.93

9.50

17.05

*Provisional

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon

rate (%)

Maturity

Date

Issue size

(Rs crore)

Complexity

level

Rating assigned

with outlook

NA

Letter of Credit

NA

NA

NA

76.55

NA

CRISIL A3+

NA

Post Shipment Credit

NA

NA

NA

90

NA

CRISIL A3+

NA

Proposed Term Loan

NA

NA

NA

31

NA

CRISIL BBB/Positive

NA

Proposed Working Capital Facility

NA

NA

NA

41.45

NA

CRISIL BBB/Positive

NA

Term Loan

NA

NA

Jun-27

74

NA

CRISIL BBB/Positive

NA

Working Capital Facility

NA

NA

NA

70

NA

CRISIL BBB/Positive

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT/ST 306.45 CRISIL A3+ / CRISIL BBB/Positive 19-01-22 CRISIL A3+ / CRISIL BBB/Positive 30-10-21 CRISIL A3+ / CRISIL BBB/Positive 09-07-20 CRISIL A3+ / CRISIL BBB/Positive 10-06-19 CRISIL A3+ / CRISIL BBB/Stable CRISIL A3+ / CRISIL BBB/Stable
      -- 13-01-22 CRISIL A3+ / CRISIL BBB/Positive   -- 07-07-20 CRISIL A3+ / CRISIL BBB/Positive   -- --
Non-Fund Based Facilities ST 76.55 CRISIL A3+ 19-01-22 CRISIL A3+ 30-10-21 CRISIL A3+ 09-07-20 CRISIL A3+ 10-06-19 CRISIL A3+ CRISIL A3+
      -- 13-01-22 CRISIL A3+   -- 07-07-20 CRISIL A3+   -- --
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Letter of Credit 76.55 Saraswat Bank CRISIL A3+
Post Shipment Credit 90 Citibank N. A. CRISIL A3+
Proposed Term Loan 31 Not Applicable CRISIL BBB/Positive
Proposed Working Capital Facility 41.45 Not Applicable CRISIL BBB/Positive
Term Loan 63 Saraswat Bank CRISIL BBB/Positive
Term Loan 4.98 Citibank N. A. CRISIL BBB/Positive
Term Loan 0.75 Standard Chartered Bank Limited CRISIL BBB/Positive
Term Loan 5.27 SVC Co-Operative Bank Limited CRISIL BBB/Positive
Working Capital Facility 60 Standard Chartered Bank Limited CRISIL BBB/Positive
Working Capital Facility 10 SVC Co-Operative Bank Limited CRISIL BBB/Positive

This Annexure has been updated on 06-Sep-2022 in line with the lender-wise facility details as on 07-Jul-2020 received from the rated entity.

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Rahul Subrato Kumar Guha
Director
CRISIL Ratings Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Ankita Gupta
Associate Director
CRISIL Ratings Limited
D:+91 22 4097 8104
ankita.gupta@crisil.com


Himanshu Khare
Senior Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Himanshu.Khare@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL’s privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale (‘report’) that is provided by CRISIL Ratings Limited (‘CRISIL Ratings’). To avoid doubt, the term ‘report’ includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, ‘CRISIL Ratings Parties’) guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html